Ernexa Therapeutics Inc.

Ernexa Therapeutics Inc. is a preclinical-stage synthetic allogeneic iMSC therapy company, with iMSCs defined as induced pluripotent stem cell (iPSC)-derived mesenchymal stem cells. The company operates in the biotechnology and pharmaceutical industries, which are characterized by rapidly advancing technologies, intense competition, and a strong emphasis on proprietary products. The company's mission is to transform the treatment of cancer and autoimmune disease by developing scalable, affordable, off-the-shelf cell therapies. Key structural forces shaping competition include the novelty of stem cell therapy, the lengthy and unpredictable regulatory approval processes of the FDA and comparable foreign authorities, and the significant capital requirements for research and development. Within this landscape, Ernexa is a preclinical-stage company with no approved products and a focus on developing its synthetic iMSC platform through internal development and strategic partnerships.

The company faces intense competition from many multinational pharmaceutical companies, established biotechnology companies, and research organizations. Primary competitors named in the filing include Mesoblast, which launched the first MSC-based therapy RYONCIL in the U.S. for steroid-refractory acute graft-versus-host disease, as well as other U.S.-based companies like BrainStorm Cell Therapeutics, RESTEM, Celltex, Baylx, Calidi Bio, Akan Biosciences, and ImStem, which are developing MSC therapies in solid tumor and inflammatory diseases. In its lead indication, platinum-resistant ovarian cancer, Ernexa faces competition from currently marketed therapies Avastin (bevacizumab) by Genentech and ELAHERE (mirvetuximab soravtansine) by ImmunoGen, as well as late-stage or clinical-stage product candidates from companies including Corcept Therapeutics, Daiichi Sankyo, Genmab, Merck & Co., and Genelux Corporation. The company believes its novel iMSC technology, expertise, technological capabilities, and scientific resources give it a strong competitive edge, but many competitors have significantly greater financial, marketing, technical, research, and human resources.

Ernexa generates revenue through an exclusive option and license agreement with a customer, which was assigned to Factor Bioscience Limited in September 2024. Under the Assignment Agreement, Factor Bioscience pays Ernexa thirty percent (30%) of all amounts it receives from the customer if the customer obtains a sublicense, and twenty percent (20%) of all amounts for customization activities. For the year ended December 31, 2025, Ernexa received approximately $0.5 million from Factor Bioscience under this agreement, recognized as other income, as it did not qualify as revenue. The company did not recognize any revenue during the year ended December 31, 2025, as it had no further obligations under the customer contract and no other revenue-generating contracts at that time. The company's primary customer segments are strategic partners for co-development or out-licensing of therapeutic assets, and it is also actively applying for research grants.

Ernexa's lead product candidate is ERNA-101, an allogenic IL-7 and IL-15-secreting iMSC, which capitalizes on the intrinsic tumor-homing ability of MSCs to deliver pro-inflammatory factors directly to the tumor microenvironment. The initial focus is to develop ERNA-101 in platinum-resistant ovarian cancer. In a preclinical study conducted with the University of Texas MD Anderson Cancer Center, ERNA-101 exhibited reduction of tumor growth and a statistically significant survival advantage in the ovarian cancer model as compared to the control group. During the fourth quarter of 2025, the company had a successful pre-IND meeting with the FDA, resulting in regulatory alignment with its development approach. The company expects to complete IND-enabling studies and IND submission in 2026 and subsequently enter a Phase 1 investigator-sponsored clinical trial in the second half of 2026.

The company is also investigating ERNA-201, an anti-inflammatory cytokine (e.g., IL-10)-secreting iMSC, in autoimmune disorders like rheumatoid arthritis. MSCs have an intrinsic ability to home to inflamed tissue and dampen inflammation, and ERNA-201 is intended to turbocharge these anti-inflammatory and regenerative effects. Additionally, Ernexa has been accepted as one of only ten global companies for the Japan External Trade Organization acceleration program, which provides expert-led mentoring, market-entry guidance focused on Japan's regulatory, clinical, and commercial landscape, and direct engagement opportunities with leading Japanese research and development organizations. The company is also actively seeking strategic partnerships to co-develop or out-license therapeutic assets and is applying for research grants, some of which will be used for research at its Texas subsidiary, Ernexa TX2, Inc.

In September 2024, Ernexa entered into the Exclusive License and Collaboration Agreement (the Factor L&C Agreement) with Factor Bioscience Limited, obtaining an exclusive license in the fields of cancer, autoimmune disorders, and rare diseases with respect to certain licensed technology. Pursuant to this agreement, Ernexa paid Factor $0.2 million per month for the first twelve months and $0.1 million per month for the first nine months toward patent costs, and will also pay certain milestone payments, royalty payments on net sales, and sublicensing fee payments. In October 2025, the company entered into a master services agreement with Cellipont Bioservices for cell and gene therapy development and manufacturing services, with a statement of work focused on engineering, differentiation, and production activities to advance ERNA-101 toward clinical trials, including a $0.1 million nonrefundable project initiation fee. During the year ended December 31, 2025, the company raised $7.2 million in gross proceeds from the 2025 Private Placement of common stock and pre-funded warrants. On February 10, 2026, the company completed a public offering for net proceeds of approximately $9.5 million from the sale of common stock and accompanying warrants. The company also received $1.5 million and $0.8 million in March 2025 from the issuance of two promissory notes, which were subsequently repaid in full for $2.3 million, including accrued interest. Effective June 2, 2025, the company filed a certificate of amendment to increase authorized shares of common stock from 100 million to 150 million and effected a 1-for-15 reverse stock split on June 10, 2025.

For the fiscal year ended December 31, 2025, Ernexa reported total revenue of $0, compared to $582,000 in the prior year. The net loss for 2025 was $14.1 million, a significant improvement from a net loss of $44.5 million in 2024. The diluted net loss per share was $2.24 in 2025, compared to $48.96 in 2024. The reduction in net loss was primarily driven by a $6.8 million decrease in total operating expenses, a $23.2 million improvement in the gain/loss on extinguishment of debt, and a $6.7 million decrease in interest expense, partially offset by a $5.8 million forward sales contract expense in 2025. As of December 31, 2025, the company had cash of approximately $1.9 million and an accumulated deficit of approximately $245.6 million.

A primary growth vector is the advancement of ERNA-101 in platinum-resistant ovarian cancer. The company expects to complete IND-enabling studies and IND submission in 2026 and subsequently enter a Phase 1 investigator-sponsored clinical trial in the second half of 2026. This is supported by a successful pre-IND meeting with the FDA during the fourth quarter of 2025, which resulted in regulatory alignment with the development approach. The company has also entered into a master services agreement with Cellipont Bioservices for manufacturing services to advance ERNA-101 toward clinical trials.

Another key growth vector is the expansion of the pipeline through ERNA-201, an anti-inflammatory cytokine-secreting iMSC for autoimmune disorders like rheumatoid arthritis, which is currently under investigation. The company is also pursuing geographic expansion through the Japan External Trade Organization acceleration program, which provides market-entry guidance and engagement opportunities with Japanese research organizations. Additionally, Ernexa is actively seeking strategic partnerships to co-develop or out-license therapeutic assets and is applying for research grants to raise non-dilutive capital, including for research at its Texas subsidiary, Ernexa TX2, Inc.

The filing does not provide specific margin trajectory, cost structure evolution, or efficiency targets.

The company expects to rely on contract manufacturing relationships for any products it may develop or acquire in the future. In October 2025, it entered into a master services agreement with Cellipont Bioservices for cell and gene therapy development and manufacturing services, with a statement of work focused on engineering, differentiation, and production activities to advance ERNA-101 toward clinical trials. As of March 12, 2026, the company had five full-time employees, including three in research and development and two in administrative positions, as well as two part-time employees in administrative positions.

The filing does not specify R&D spending levels, capital expenditure plans, share repurchase authorization amounts, or dividend policy for the upcoming period beyond the general expectation to continue incurring losses.

A significant headwind is the company's need for substantial additional capital to fund its operations. Based on its current financial condition and forecasts, management states it will not have sufficient capital to fund operations for the 12 months following the issuance date of the consolidated financial statements. The company's ability to raise capital is subject to market conditions, the trading price of its stock, and investor sentiment, and there is no assurance that capital will be available on favorable terms or at all.

The company faces a specific regulatory and listing constraint related to Nasdaq compliance. Its stockholders' equity at December 31, 2025 was approximately $2.4 million, and it did not meet the MVLS Rule or the Net Income Rule. While a subsequent public offering on February 10, 2026 brought stockholders' equity above $2.5 million, the closing bid price of its common stock has been trading below $1.00 since February 3, 2026. Because the company effected a reverse stock split within the last 12 months to regain compliance with the Bid Price Rule, it would not be eligible for a compliance period under Nasdaq rules if it fails to meet the minimum bid price requirement within one year, potentially leading to delisting.

The most material risk is the company's need for substantial additional capital to fund operations, as management states it will not have sufficient capital to fund operations for the 12 months following the issuance date of the financial statements, raising substantial doubt about its ability to continue as a going concern. The company has incurred significant net losses since inception, with an accumulated deficit of approximately $245.6 million ¹ as of December 31, 2025. A second critical risk is the company's reliance on in-licensed intellectual property from Factor Bioscience Limited under the Factor L&C Agreement; loss of this license or termination of the agreement could significantly harm product development and the ability to enter co-development partnerships. A third risk is the failure to meet Nasdaq continued listing requirements, as the company's stockholders' equity was approximately $2.4 million ² at December 31, 2025, and its common stock has been trading below $1.00 since February 3, 2026, which could lead to delisting. Finally, the company's product development relies on novel, inherently risky stem cell therapy technology, and the regulatory approval process is lengthy, time-consuming, and unpredictable, with no iPSC-derived cell products currently approved for commercial sale anywhere in the world.

Management's message to shareholders, as conveyed through the 10-K filing, emphasizes the company's mission to transform the treatment of cancer and autoimmune disease by developing scalable, affordable, off-the-shelf cell therapies. The tone is forward-looking but cautious, highlighting significant progress in the development of its lead candidate ERNA-101, including a successful pre-IND meeting with the FDA and regulatory alignment on the development approach. Management's strategic priorities for the period ahead are: (1) advancing ERNA-101 toward a Phase 1 clinical trial in platinum-resistant ovarian cancer, with expectations to complete IND-enabling studies and IND submission in 2026; (2) expanding developmental opportunities through strategic partnerships to co-develop or out-license therapeutic assets and applying for research grants; and (3) addressing the company's substantial capital requirements, as management explicitly states that based on current financial condition and forecasts, the company will not have sufficient capital to fund operations for the 12 months following the issuance date of the financial statements.